As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
News|Articles|February 4, 2026
6 Psychiatry Headlines You Missed in January 2026
Author(s)Chelsie Derman
Fact checked by: Alex Hillenbrand
FDA approvals, priority review decisions, and new data on treatment response and mechanisms highlight a month of progress in MDD and ADHD.
Advertisement
Advertisement
January 2026 delivered a wave of consequential developments across psychiatry, spanning regulatory milestones, predictive treatment insights, and emerging biological and therapeutic frameworks for depression and ADHD. From the
Related to this article
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Advertisement
Advertisement